中东和非洲多发性硬化症治疗市场预测至 2027 年 - COVID-19 影响和按药物类别（免疫抑制剂和免疫调节剂）、给药途径（注射和口服）和分销渠道（医院药房、零售药房和电子渠道）进行的区域分析商业）
No. of Pages: 128 | Report Code: TIPRE00022636 | Category: Life Sciences
No. of Pages: 128 | Report Code: TIPRE00022636 | Category: Life Sciences
多发性硬化症（MS）是一种影响中枢神经系统的自身免疫性疾病。多发性硬化症是一种广泛存在的致残性神经系统疾病，大多数在 20-50 岁年龄段的人群中被诊断出来。这是一种潜在的使人衰弱的疾病，会导致身体的沟通和协调功能中断。
中东和非洲多发性硬化症治疗市场预计将从2019年的13.1908亿美元增至2027年的20.2786亿美元；预计 2020 年至 2027 年复合年增长率为 5.7%。市场的增长归因于一些关键驱动因素，例如人们对多发性硬化症的认识不断提高，以及创新产品的开发和推出。然而，多发性硬化症治疗的高成本阻碍了市场的增长。
多发性硬化症（MS）是一种影响大脑、脊髓和视神经的慢性疾病。研究表明，中东和非洲国家多发性硬化症的患病率有所增加。近年来，人们采取了各种措施和努力来提高人们对神经系统疾病的认识并进行教育，这有助于患者获得适合此类疾病的药物和治疗。多发性硬化症基金会及其附属团体发起了全国多发性硬化症教育和宣传月，自 2003 年起每年三月举办该活动，以提高对该疾病的认识。该计划的目标是促进对多发性硬化症的了解，并帮助患者做出明智的治疗决定。此外，国家 MS 协会创建并启动了“MS Kills Connection” <连接杀死MS”该活动旨在将多发性硬化症患者、治疗多发性硬化症患者的人们以及开展活动以创造一个没有多发性硬化症的世界的人们联系起来。同样，多发性硬化症治疗市场的几家参与者正在开发和推出新产品。地理和制造能力扩张战略以及产品发布有助于公司迎合广泛的客户群。此类新产品的开发和推出正在成为中东和非洲多发性硬化症治疗市场的主要趋势。
中东和非洲的新冠肺炎病例数量不断增加19 例。 2020 年，COVID-19 大流行限制了该地区各国的研发活动。除此之外，大量人口已经面临高血压和糖尿病等非传染性疾病的日益沉重的负担，这使他们更容易受到新冠病毒的影响。冠状病毒。这些地区国家高度依赖从发达国家进口的药品。因此，供应链的大规模中断正在阻碍中东和非洲多发性硬化症治疗市场的增长。
< strong>主要细分市场
中东和非洲多发性硬化症治疗市场按药物类别分为免疫抑制剂和免疫调节剂。免疫调节剂细分市场在 2019 年占据了较大的市场份额，而免疫抑制剂细分市场预计在预测期内将实现更高的复合年增长率。
中东和非洲非洲多发性硬化症治疗市场按给药途径分为注射剂和口服剂。注射剂细分市场在 2019 年占据了更大的市场份额，预计该细分市场在预测期内的市场复合年增长率将更高。
基于分销渠道中东和非洲多发性硬化症治疗市场分为医院药房、零售药房和电子商务。医院药房细分市场在 2019 年占据最大市场份额。然而，预计电子商务细分市场在预测期内的复合年增长率最高。
一些与本中东和非洲多发性硬化症治疗市场报告相关的主要和次要来源包括多发性硬化症科学研究基金会 (MSSRF)、世界卫生组织 (WHO) 和卫生与预防部 (MoHAP)。
Strategic insights for Middle East and Africa Multiple Sclerosis Therapeutics involve closely monitoring industry trends, consumer behaviours, and competitor actions to identify opportunities for growth. By leveraging data analytics, businesses can anticipate market shifts and make informed decisions that align with evolving customer needs. Understanding these dynamics helps companies adjust their strategies proactively, enhance customer engagement, and strengthen their competitive edge. Building strong relationships with stakeholders and staying agile in response to changes ensures long-term success in any market.
| Report Attribute | Details |
|---|---|
| Market size in 2019 | US$ 1,319.08 Million |
| Market Size by 2027 | US$ 2,027.86 Million |
| Global CAGR (2020 - 2027) | 5.7% |
| Historical Data | 2017-2018 |
| Forecast period | 2020-2027 |
| Segments Covered |
By 药物类别
|
| Regions and Countries Covered | 中东和非洲
|
| Market leaders and key company profiles |
The regional scope of Middle East and Africa Multiple Sclerosis Therapeutics refers to the geographical area in which a business operates and competes. Understanding regional nuances, such as local consumer preferences, economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved regions or adapting their offerings to meet regional demands. A clear regional focus allows for more effective resource allocation, targeted marketing, and better positioning against local competitors, ultimately driving growth in those specific areas.
The Middle East and Africa Multiple Sclerosis Therapeutics Market is valued at US$ 1,319.08 Million in 2019, it is projected to reach US$ 2,027.86 Million by 2027.
As per our report Middle East and Africa Multiple Sclerosis Therapeutics Market, the market size is valued at US$ 1,319.08 Million in 2019, projecting it to reach US$ 2,027.86 Million by 2027. This translates to a CAGR of approximately 5.7% during the forecast period.
The Middle East and Africa Multiple Sclerosis Therapeutics Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Middle East and Africa Multiple Sclerosis Therapeutics Market report:
The Middle East and Africa Multiple Sclerosis Therapeutics Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Middle East and Africa Multiple Sclerosis Therapeutics Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Middle East and Africa Multiple Sclerosis Therapeutics Market value chain can benefit from the information contained in a comprehensive market report.
Office No. 1011, First floor, Farena Corporate Park, Magarpatta-Mundhwa road, Pune - 411028, Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For Middle East and Africa Multiple Sclerosis Therapeutics Market
